FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210308521> ?p ?o ?g. }

• W4210308521 abstract "Background Cerebrolysin is a mixture of low‐molecular‐weight peptides and amino acids derived from pigs' brain tissue, which has potential neuroprotective and neurotrophic properties. It is widely used in the treatment of acute ischaemic stroke in Russia, China, and other Asian and post‐Soviet countries. Objectives To assess the benefits and risks of Cerebrolysin for treating acute ischaemic stroke. Search methods We searched the Cochrane Stroke Group Trials Register (October 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (November 2014), MEDLINE (1966 to November 2014), EMBASE (1974 to November 2014), Web of Science Core Collection, with Science Citation Index (1940 to November 2014), LILACS (1982 to December 2014), OpenGrey (1980 to December 2014), and a number of Russian Databases (1998 to December 2014). We also searched reference lists, ongoing trials registers and conference proceedings, and contacted the manufacturer of Cerebrolysin, EVER Neuro Pharma GmbH (formerly Ebewe Pharma). Selection criteria Randomised controlled trials comparing Cerebrolysin started within 48 hours of stroke onset and continued for at least two weeks with placebo or no treatment in people with acute ischaemic stroke. Data collection and analysis Two review authors independently applied inclusion criteria, assessed trial quality and risk of bias, and extracted data. Main results We included one trial involving 146 participants. We evaluated risk of bias and judged it to be high for generation of allocation sequence, low for allocation concealment, high for incomplete outcome data (attrition bias), unclear for blinding, high for selective reporting and high for other sources of bias. The manufacturer of Cerebrolysin, pharmaceutical company Ebewe, provided Cerebrolysin and the placebo, as well as the randomisation codes. There was no difference in the number of deaths (6/78 in Cerebrolysin group versus 6/68 in placebo group; risk ratio (RR) 0.87, 95% confidence interval (CI) 0.29 to 2.58) or in the total number of adverse events (16.4% versus 10.3%; RR 1.62, 95% CI 0.69 to 3.82) between the treatment and control groups. Authors' conclusions Routine administration of Cerebrolysin to people with acute ischaemic stroke cannot be supported by the available evidence from RCTs." @default.
• W4210308521 created "2022-02-08" @default.
• W4210308521 creator A5028204642 @default.
• W4210308521 creator A5050095533 @default.
• W4210308521 date "2015-06-17" @default.
• W4210308521 modified "2023-10-17" @default.
• W4210308521 title "Cerebrolysin for acute ischaemic stroke" @default.
• W4210308521 cites W1486400768 @default.
• W4210308521 cites W1695543549 @default.
• W4210308521 cites W1711048317 @default.
• W4210308521 cites W1871009028 @default.
• W4210308521 cites W1913839478 @default.
• W4210308521 cites W1915763889 @default.
• W4210308521 cites W1929039485 @default.
• W4210308521 cites W1959848988 @default.
• W4210308521 cites W1981795381 @default.
• W4210308521 cites W1990040619 @default.
• W4210308521 cites W2000949542 @default.
• W4210308521 cites W2014895186 @default.
• W4210308521 cites W2017141784 @default.
• W4210308521 cites W2022180257 @default.
• W4210308521 cites W2023528825 @default.
• W4210308521 cites W2041645861 @default.
• W4210308521 cites W2046416946 @default.
• W4210308521 cites W2085878408 @default.
• W4210308521 cites W2086336907 @default.
• W4210308521 cites W2087099426 @default.
• W4210308521 cites W2099803755 @default.
• W4210308521 cites W2131499646 @default.
• W4210308521 cites W2136280619 @default.
• W4210308521 cites W2142482904 @default.
• W4210308521 cites W2142960568 @default.
• W4210308521 cites W2150647647 @default.
• W4210308521 cites W2156048108 @default.
• W4210308521 cites W2161871718 @default.
• W4210308521 cites W2165010366 @default.
• W4210308521 cites W2165568749 @default.
• W4210308521 cites W2171116737 @default.
• W4210308521 cites W2172592185 @default.
• W4210308521 cites W2178033301 @default.
• W4210308521 cites W2179137398 @default.
• W4210308521 cites W2180717194 @default.
• W4210308521 cites W2181047592 @default.
• W4210308521 cites W2274317172 @default.
• W4210308521 cites W2312654759 @default.
• W4210308521 cites W2395535723 @default.
• W4210308521 cites W2401631967 @default.
• W4210308521 cites W2409211243 @default.
• W4210308521 cites W2461929879 @default.
• W4210308521 cites W2561853855 @default.
• W4210308521 cites W2761679643 @default.
• W4210308521 cites W2917324771 @default.
• W4210308521 cites W2918698433 @default.
• W4210308521 cites W3016098966 @default.
• W4210308521 cites W3016654034 @default.
• W4210308521 cites W4210322085 @default.
• W4210308521 cites W4210736707 @default.
• W4210308521 cites W4235542203 @default.
• W4210308521 cites W4235709477 @default.
• W4210308521 cites W4241761563 @default.
• W4210308521 cites W4242069899 @default.
• W4210308521 cites W4247947258 @default.
• W4210308521 cites W4312722514 @default.
• W4210308521 doi "https://doi.org/10.1002/14651858.cd007026.pub3" @default.
• W4210308521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26083192" @default.
• W4210308521 hasPublicationYear "2015" @default.
• W4210308521 type Work @default.
• W4210308521 citedByCount "13" @default.
• W4210308521 countsByYear W42103085212016 @default.
• W4210308521 countsByYear W42103085212017 @default.
• W4210308521 countsByYear W42103085212018 @default.
• W4210308521 countsByYear W42103085212019 @default.
• W4210308521 countsByYear W42103085212020 @default.
• W4210308521 countsByYear W42103085212023 @default.
• W4210308521 crossrefType "reference-entry" @default.
• W4210308521 hasAuthorship W4210308521A5028204642 @default.
• W4210308521 hasAuthorship W4210308521A5050095533 @default.
• W4210308521 hasConcept C126322002 @default.
• W4210308521 hasConcept C127413603 @default.
• W4210308521 hasConcept C142724271 @default.
• W4210308521 hasConcept C17744445 @default.
• W4210308521 hasConcept C1862650 @default.
• W4210308521 hasConcept C199539241 @default.
• W4210308521 hasConcept C204787440 @default.
• W4210308521 hasConcept C27081682 @default.
• W4210308521 hasConcept C2771230 @default.
• W4210308521 hasConcept C2776149669 @default.
• W4210308521 hasConcept C2776478404 @default.
• W4210308521 hasConcept C2779473830 @default.
• W4210308521 hasConcept C2780645631 @default.
• W4210308521 hasConcept C535046627 @default.
• W4210308521 hasConcept C71924100 @default.
• W4210308521 hasConcept C78519656 @default.
• W4210308521 hasConcept C95190672 @default.
• W4210308521 hasConceptScore W4210308521C126322002 @default.
• W4210308521 hasConceptScore W4210308521C127413603 @default.
• W4210308521 hasConceptScore W4210308521C142724271 @default.
• W4210308521 hasConceptScore W4210308521C17744445 @default.
• W4210308521 hasConceptScore W4210308521C1862650 @default.
• W4210308521 hasConceptScore W4210308521C199539241 @default.

• next